Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model
Author:
Open Access
- 1 January 2011
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 17 (44) , 4858-66
Abstract
To investigate the role of epidermal growth factor receptor (EGFR) in colitis-associated dysplasia using the EGFR tyrosine kinase inhibitor erlotinib. Sprague-Dawley rats received trinitrobenzene sulfonic acid (TNBS; 30 mg in 50% ethanol, ic), followed 6 wk later by reactivation with TNBS (5 mg/kg, iv) for 3 d. To induce colitis-associated dysplasia, rats then received TNBS (iv) twice a week for 10 wk. One group received erlotinib (10 mg/kg, ip) for 1 wk before the start of the reactivation of the colitis and 2 wk after (21 d); the rest received the vehicle. After rats were euthanized, the colons were removed and analyzed for damage and expression of the EGFR downstream effectors Erk1/2 and c-Myc. Ninety percent of the vehicle-treated animals had dysplasia in any region of the colon. Erlotinib-treated animals had a significant decrease in the incidence of dysplasia compared to vehicle-treated animals in all regions of the colon (50.00% ± 11.47% vs 90.00% ± 10.00% in proximal, P < 0.05; 15.00% ± 8.19% vs 50.00% ± 16.67% in mid, P < 0.05; and 20.00% ± 9.17% vs 70.00% ± 15.28% in distal, P < 0.01). Erlotinib-treated animals also had reduced cell proliferation, reduced active Erk1/2, and reduced c-Myc in colon epithelium compared with the vehicle-treated animals. In vitro, erlotinib treatment was shown to markedly decrease c-Myc and pErk1/2 levels in rat epithelial cells. Proliferation of rat epithelial cells was stimulated by epidermal growth factor and inhibited by erlotinib (P < 0.05). Erlotinib can decrease the development of colitis-associated dysplasia, suggesting a potential therapeutic use for erlotinib in patients with long-standing colitis.Keywords
This publication has 23 references indexed in Scilit:
- EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)International Journal of Oncology, 2003
- Chronic Inflammation Alters Protein Metabolism in Several Organs of Adult RatsThe Journal of Nutrition, 2002
- Protective effects of neurokinin‐1 receptor during colitis in mice: role of the epidermal growth factor receptorBritish Journal of Pharmacology, 2002
- Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic MiceThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Keratinocyte growth factor promotes healing of left-sided colon anastomosesThe American Journal of Surgery, 1998
- Cancer and Inflammatory Bowel Disease: Bias, Epidemiology, Surveillance, and TreatmentWorld Journal of Surgery, 1998
- Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer.1997
- Experimental models of inflammatory bowel diseaseGastroenterology, 1995
- Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1995
- Protective effect of epidermal growth factor in an experimental model of colitis in ratsGastroenterology, 1994